Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs iShares Global Clean Energy ETF (ICLN) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
iShares Global Clean Energy ETFTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs iShares Global Clean Energy ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while iShares Global Clean Energy ETF trades at $18.38. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals.

BIOICLN
Market Cap
$9.39B
Sector
Health
52-Week High
$356.25$23.75
52-Week Low
$241.71$13.66
Enterprise Value
$9.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.

The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.

iShares Global Clean Energy ETF

ICLN trades at $18.30, up 0.99% today, but technical indicators signal a bearish trend with resistance near $19. The ETF lacks key valuation metrics like P/E and P/S due to its structure, and recent news highlights competition from traditional energy ETFs offering higher yields and lower fees. Clean energy faces policy risks, with stalled U.S. permits threatening investment, though global demand for renewables remains strong.

Outlook is cautious; ICLN offers growth exposure to 105 global clean energy firms but underperforms peers on fees and dividends. Risks include regulatory uncertainty and volatility, while analyst sentiment is mixed amid sector comparisons. Investors should weigh long-term green energy trends against near-term headwinds.

Returns comparison

Trailing returns across standard periods

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About iShares Global Clean Energy ETF

The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.

Read more on ICLN